Table 5.
Characteristics of the AVERT and CASSINI trials.
Study Characteristics | AVERT | CASSINI |
---|---|---|
Intervention | Apixaban 2 × 2.5 mg/d | Rivaroxaban 10 mg/d |
Type of cancer | Lymphoma 25%, gynecologic 26%, pancreas 13%, lung 10% | Pancreas 33%, upper GI 21%, lung 15%, lymphoma 7% |
Outcome definition | Symptomatic or incidental VTE | Symptomatic or incidental VTE or VTE death * |
VTE rate in control group | 10.2% | 8.8% |
Mortality in control group | 9.8% | 23.8% |
* Systematic DVT screening, VTE: venous thromboembolism.